BBO-11818 in Adult Subjects With KRAS Mutant Cancer
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
Checked against the public recordLast updated Jun 2, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Interventions being studied
- Drug: BBO-11818; Drug: Pembrolizumab; Drug: Platinum chemotherapy (cisplatin or carboplatin); Drug: Pemetrexed; Drug: Cetuximab; Drug: mFOLFOX6; Drug: mFOLFOX6; Drug: BBO-10203; Drug: mFOLFIRINOX; Drug: Gemcitabine; Drug: Nab-paclitaxel
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation * Measurable disease by RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 * Life expectancy \>24 weeks * Adequate organ function Exclusion Criteria: * Malignancy within the last 2 years as specified in the protocol * Untreated brain metastases Other inclusion/exclusion criteria are specified in the protocol.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- The Angeles Clinic and Research Institute - West Los Angeles OfficeLos Angeles, California
- University of California DavisSacramento, California
- University of California San Diego Moores Cancer CenterSan Diego, California
- University of California San Francisco Helen Diller Family Comprehensive Cancer CenterSan Francisco, California
- Yale UniversityNew Haven, Connecticut
- Moffitt Cancer CenterTampa, Florida
- OSF Healthcare Cancer InstitutePeoria, Illinois
- Massachusetts General HospitalBoston, Massachusetts
- NYU Langone HealthNew York, New York
- Columbia University Irving Medical CenterNew York, New York
- Vanderbilt University Medical CenterNashville, Tennessee
- Sarah Cannon Research Institute at Mary CrowleyDallas, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 2, 2026. Always confirm current availability with the study team.